Text Size

Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00396110
First received: November 3, 2006
Last updated: NA
Last verified: February 2003
History: No changes posted
  Purpose

In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C < 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.


Condition Phase
Hypercholesterolemia
Coronary Heart Disease
 Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Estimated Enrollment: 3889
Study Start Date: February 2003
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • High-risk patients with and without evident CHD who had LDL-C > 3.2 mmol/l and were treated at that moment with HMG-CoA-reductase inhibitor apart from rosuvastatin.
  • Patients were aged >18 years and <70 years (men) and < 75 years (women).

Exclusion Criteria:

  • Treatment with atorvastatin 40 or 80 mg or simvastatin 80 mg
  • Patients familiar with muscular pain, myopathy or liver function disorders (inclusive elevation of serum transaminases) and/or contra-indications for treatment with rosuvastatin
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00396110

Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Ingrid van Geel, MD AstraZeneca
Study Chair: Ingeborg Vosjan, MD AstraZeneca
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00396110     History of Changes
Other Study ID Numbers: 25V06, TARGET
Study First Received: November 3, 2006
Last Updated: November 3, 2006
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by AstraZeneca:
cholesterol
coronary heart disease
rosuvastatin
LDL-C goal
hypercholesterolemia

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Hypercholesterolemia
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
 Metabolic Diseases
Rosuvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 19, 2013